Connect with us


Parexel appoints Gwyn Bebb as Senior Vice President and Global Therapeutic Area Head for Oncology



Past- Clinical Research Medical Director, Amgen

Present- Senior Vice President and Global Therapeutic Area Head for Oncology, Parexel

Parexel, a globally recognized Clinical Research Organization (CRO) offering comprehensive Phase I to IV clinical development services, has officially appointed Dr. Gwyn Bebb as Senior Vice President and Global Therapeutic Area Head – Oncology.

In this role, Dr. Bebb will spearhead the research and development efforts aimed at pioneering innovative cancer treatments for biopharmaceutical clients across the globe.

Dr. Bebb, who is a licensed medical oncologist with over two decades of expertise spanning academia, clinical research, and the biotechnology sectors, brings a wealth of experience to his new role. His most recent position was as a Clinical Research Medical Director at Amgen, where he played a pivotal role in advancing early- and late-stage oncology drug development. Notably, he led a biphasic T cell engager program to the critical Phase III trial stage.

His experience also includes serving as a professor in the Department of Medicine at the University of Calgary (Alberta, Canada), where he established the Precision Oncology Experimental Therapeutics (POET) program and directed the Clinical Trials Unit at the Tom Baker Cancer Centre.

While at the University of Calgary, Dr. Bebb founded and directed a provincial lung cancer database (the Glans Look Lung Cancer Database) to examine the association between real world patient outcomes and molecular markers being studied in his research lab. His experience also includes clinical practice as a Medical Oncologist focused on lung and gastrointestinal cancers.

“There is tremendous unmet medical need for patients with cancer representing an important priority for our customers and Parexel,” added Peyton Howell, Chief Operating and Growth Officer. “We’re pleased to continue expanding our expertise and leadership in this important therapeutic area and others — reinforcing our unwavering commitment to patients.”

A fluent Welsh speaker, Dr. Bebb earned his undergraduate degree in Natural Science from the University of Cambridge, England; his medical degree from the University of Oxford, England; and a Doctor of Philosophy in Molecular Pathology from the University of British Columbia, Vancouver, Canada.